FITC- und PE-markierte Proteine für die Entwicklung von biologischen Arzneimitteln

FACS Analysis of Anti-CD19 CAR Expression

293 cells were transfected with anti-CD19-scFv and RFP tag. 2e5 of the cells were stained with FITC-Labeled Human CD19 (20-291), Fc Tag (Cat. No. CD9-HF251, 10 μg/ml) and FITC-labeled protein control. Non-transfected 293 cells and FITC-labeled protein control were used as negative control. RFP was used to evaluate CAR (anti-CD19-scFv) expression and FITC was used to evaluate the binding activity of FITC-Labeled Human CD19 (20-291), Fc Tag (Cat. No. CD9-HF251) (QC tested).                        

Flow Cytometry assay shows that PE-Labeled Human PD-1, Fc Tag, His Tag (recommended for neutralizing assay) (Cat. No. PD1-HP2F2) can bind to 293T cells overexpressing human PD-L1. 1μl stock solution per million cells (QC tested).

FACS analysis shows that the binding of PE-Labeled Human PD-1, Fc Tag, His Tag (recommended for neutralizing assay) (Cat. No.PD1-HP2F2) to 293T overexpressing PD-L1 was inhibited by increasing concentration of neutralizing antihuman PD-L1 antibody. The IC50 is 0.29 μg/ml (QC tested).

Binding activity of the Human MSLN, Fc Tag before and after FITC labeling was evaluated in the above ELISA analysis. The result shows that FITC-Labeled and Unconjugated Human MSLN, Fc Tag have almost the same level of binding activity.